(via TheNewswire)
![]() | |||||||||
![]() | ![]() | ![]() | ![]() | ![]() |
2022 Highlights:
Advancing the Planned Clinical Trial Application. UI has designated semi-synthesised Ibogaine HCL (ibogaine hydrochloride) for its initial clinical trial for the treatment of opioid use disorder utilizing the proprietary ibogaine treatment protocol which has now been administered an industry leading 4000 treatments without issue at the UI partner clinic
Developing Drug Supply Relationships. While medical grade supplies of psilocybin and MDMA are becoming readily available for research, UI faced challenges in securing an economic supply of ibogaine for use in the planned clinical trial.
Developed Business Model and Financial Forecast. The size of the opioid problem and the nature of solution delivery indicated a business model that leveraged the existing network of detox and treatment centers across the
Major Overhaul of Kelburn Facilities– A series of natural events caused the closure of the Kelburn facility which allowed the team to complete a major overhaul of both the physical facility and treatment programming. The renovation will increase patient capacity and facilitate ibogaine treatment on the completion of trials. A comprehensive update of the addiction treatment program was completed as well, which will place Kelburn in a leading position globally, offering the best in proven evidence based programming as well as the latest bespoke nuovo modalities. The Kelburn facility is looking to re-open
About
UI is a life sciences company,with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that protocol globally through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", "potential", or other similar words, or statements that certain events or conditions "may", "should" or "could" occur. The forward-looking statements and information are based on certain key expectations and assumptions made by UI. Although UI believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because UI can give no assurance that they will prove to be correct.
Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, which include, but are not limited to, risks that required regulatory approvals are not obtained. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by UI at the time of preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on forward-looking information, which speaks only to conditions as of the date hereof. UI does not undertake any obligation to release publicly any revisions to forward-looking information contained herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.
For further information:
Investor Relations:
dugan.selkirk@universalibogaine.com
Related Links
https://universalibogaine.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source